Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

866
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
866
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

704
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
704
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.4K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.4K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.5K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.5K
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

2.1K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
2.1K
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

467
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
467

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Post-Tuberculosis Lung Disease: The Role of Surgical Management.

Thoracic surgery clinics·2026
Same author

Surgery for Active and Drug-Resistant Tuberculosis.

Thoracic surgery clinics·2026
Same author

World TB Day 2026: Scientific innovation across the tuberculosis continuum must now translate into global impact.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

Do we need to revise the dose of isoniazid for the treatment of tuberculosis in children?

The European respiratory journal·2026
Same author

Feasibility and efficacy of a population-based pulmonary rehabilitation for post-tuberculosis lung disease in Bangladesh.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

Functional capacity and quality of life after telerehabilitation in post-tuberculosis lung disease: a randomized controlled trial.

Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia·2026

Related Experiment Video

Updated: Apr 1, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.4K

Update on Tuberculosis Treatment and Drug Regimens.

Rosella Centis1, Lia D'Ambrosio2, Giovanni Battista Migliori3

  • 1Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Tradate 21049, Italy.

Cold Spring Harbor Perspectives in Medicine
|March 30, 2026
PubMed
Summary
This summary is machine-generated.

Adherence to tuberculosis treatment is vital for effectiveness. New drugs offer hope for drug-resistant tuberculosis, but challenges remain, necessitating further research and public health policies.

More Related Videos

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.2K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.4K

Related Experiment Videos

Last Updated: Apr 1, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.4K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.2K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.4K

Area of Science:

  • Infectious Diseases
  • Public Health
  • Pharmacology

Background:

  • Tuberculosis (TB) is an airborne infectious disease requiring combination therapy.
  • Adherence to long-term antituberculosis therapy is critical for maintaining adequate blood drug levels.
  • Inadequate medical management contributes to the emergence and spread of drug-resistant Mycobacterium tuberculosis strains.

Purpose of the Study:

  • To review the current landscape of tuberculosis treatment, including challenges posed by drug resistance.
  • To highlight the impact of new antituberculosis drugs and regimens.
  • To emphasize the need for continued research and public health strategies for tuberculosis management.

Main Methods:

  • Literature review of current antituberculosis therapies.
  • Analysis of the emergence and spread of drug-resistant Mycobacterium tuberculosis.
  • Evaluation of new antituberculosis drugs and regimens, including bedaquiline, delamanid, and pretomanid.
  • Consideration of post-tuberculosis lung disease.

Main Results:

  • New antituberculosis regimens have been approved, shortening treatment duration for both drug-susceptible and drug-resistant TB.
  • New drugs like bedaquiline, delamanid, and pretomanid offer alternatives but are not definitive solutions, especially in intermediate-economy settings.
  • Post-tuberculosis lung disease presents a significant burden, requiring effective prevention and rehabilitation strategies.

Conclusions:

  • Despite advances, managing drug-resistant tuberculosis remains challenging, particularly in resource-limited settings.
  • New drugs and shorter regimens are promising but require careful implementation and monitoring.
  • Urgent research, development, and robust public health policies are essential to preserve therapeutic options and address the evolving TB epidemic.